Abstract: The invention relates to compounds of general formula I

Abstract: A soluble, heterodimeric interleukin 18 (IL-18) receptor molecule is described which comprises two subunits, one of which comprises an extracelluar domain, or a fragment thereof, of IL-18R, and the other of which comprises an extracelluar domain, or a fragment thereof, of AcPL. Preferably, the soluble, heterodimeric receptor binds to IL-18 with higher affinity than does either IL-18R or AcPL alone.

Abstract: A bispecific monoclonal antibody is described which comprises two moieties, one of which comprises an antigen-binding region which is specific for either the IL-12R&bgr;1 or the IL-12R&bgr;2 subunit of an IL-12 receptor, and the other of which comprises an antigen-binding region which is specific for either the IL-18R or the AcPL subunit of an IL-18 receptor.

Abstract: Benzimidazoles of general formula I 1

Abstract: The invention describes the regulation of cervical dilatation and extensibility by the use of nitric oxide donors and/or substrates or nitric oxide inhibitors. There can be used either (a) at least one nitric oxide donor and/or substrate for manufacture of a medicament to be administered locally intracervically or intravaginally for induction of cervical ripening or (b) at least one nitric oxide inhibitor for manufacture of a medicament to be administered locally intracervically or intravaginally for treatment of cercvical insufficiency or preterm labor.

Abstract: The invention relates to compounds of formula (I): Fm(—A1)(—Bn)(—Wo) wherein F is a colorant-signal molecule with a maximum absorption value ranging from 600-1200 nm; A is a &bgr;-amyloid plaque binding biomolecule; B is a &bgr;-amyloid plaque binding colorant; and W is a &bgr;-amyloid plaque binding hydrophilic low-molecular structural element. The invention also describes the use of these compounds in in vivo an din vitro diagnosis of neurodegenerative diseases such as Alzheimer's disease by means of near infra-red radiation (NIR radiation) as a constrasting agent in fluoresecence and transillumination diagnosis in the NIR range. Diagnostic agents containing said componenets are also disclosed.

Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.

Abstract: Pharmaceutical agents that contain perfluoroalkyl-containing metal complexes are useful in tumor therapy and interventional radiology.

Abstract: A prefilled medicinal syringe includes a cylinder with a proximal end, a distal end and an outlet. The syringe contains a medicine or a diagnostic agent which is ejected therefrom by a plug. The surfaces of the plug which touch the inside wall of the cylinder are preferably made of polytetrafluoroethylene (TEFLON.RTM.). Preferably the material of which the inside wall of the cylinder is made directly touches the TEFLON.RTM. surfaces of the plug. The plug has at least one sealing lip which forms an acute angle with the axis of the syringe and extends in a direction toward the distal end of the syringe. By so configuring the plug, the prefilled syringe may be autoclaved, stored for an extended time, and still function smoothly without leakage.

Abstract: Steroid esters of formula I ##STR1## are described, wherein m, n and x are as defined by the specification. The compounds are distinguished from the basic hydroxy compounds by considerably improved solubility as well by increased biological activity and selectivity.The compounds are suitable for the production of pharmaceutical agents.

Abstract: The present invention describes a two-stage pharmaceutical combined preparation for hormonal contraception containing at least 30 daily unit doses, which preparation, in its first stage, comprises as hormonal active ingredient a combination of an oestrogen preparation and, in a dose that is at least sufficient to inhibit ovulation, a gestagen preparation, in single stage form and, in the second stage comprises as hormonal active ingredient an oestrogen preparation only, wherein the first stage comprises a minimum of 25 and a maximum of 77 daily discrete or continuous unit doses and the second stage comprises 5, 6 or 7 daily discrete or continuous unit doses, and wherein the total number of daily units is equal to the total number of days of the desired cycle of a minimum of 30 and a maximum of 84 days.

Abstract: The invention relates to a process for magnetorelaxometric quantitative detection of analytes in liquid and solid phases, compounds for magnetorelaxometric detection, and their use in analysis and immunomagnetography.

Abstract: This invention describes new, substituted 7.alpha.-(.xi.-aminoalkyl)-estratrienes of general formula I ##STR1## in which side chain SK is a radical of partial formula ##STR2## as well as their physiologically compatible addition salts with organic and inorganic acids.The new compounds represent compounds with very strong antiestrogenic action.The compounds according to the invention are, on the one hand, pure antiestrogens, or, on the other hand, antiestrogens with estrogenic partial action. Based on this spectrum of action, the new compounds are highly suitable for the production of pharmaceutical agents for tumor therapy and hormone replacement treatment.

Abstract: The invention provides a pharmaceutical combination preparation with two hormone components in a packaging unit and intended for time-sequential oral administration, comprising a number of daily dosage units physically separate and individually removable in the packaging unit, whereby as a hormonal active ingredient a first hormone component contains in combination an estrogen preparation and in at least a dosage that is sufficient to inhibit ovulation a gestagen preparation, and as a hormonal active ingredient the second hormone component contains only an estrogen preparation, whereby the first hormone component comprises 23 or 24 daily units and the second hormone component comprises 4, 3 or 2 daily units, and between these two hormone components, 2 or 1 active ingredient-free daily units are present or 2 or 1 blank pill days are indicated, and the total number of hormone daily units and the active ingredient-free daily units or the blank pill days is equal to the total number of days of the desired cycle,

Abstract: The invention concernes borneol esters of general formula (I), in which R.sup.1 means T--C(O)--CH(OR.sup.6)--(NR.sup.7a R.sup.7b)--R.sup.8, C(O)--CH(OR.sup.6a)--CH[NR.sup.7 (C(O)--CH(OR.sup.6b)--CH (NR.sup.7a R.sup.7b)--R.sup.8a)]--R.sup.8b ; R.sup.7a R.sup.7b are identical or different and means R.sup.7 ; R.sup.7 means hydrogen, A, --C(O)R.sup.12, --C(O)OR.sup.12, --C(O)SR.sup.12, --C(O)NHR.sup.9d, --C(O)NR.sup.9d R.sup.9e, --SO.sub.2 R.sup.12, C.sub.1 -C.sub.10 alkyl; R.sup.8a, R.sup.8b are identical or different and mean R.sup.8 ; R.sup.8 means (i), heteroaryl substituted by X.sup.3, C.sub.7 -C.sub.16 aralkyl, alkyl; A is B--[O--(CH.sub.2).sub.t --C(O)].sub.0 or 1-, farnesyl--P(O)(OR.sup.9d)--O--(CH.sub.2).sub.t --C(O)--; B means protein kinase-inhibitors or farnesyl protein transferase-inhibitors such as for example farnesyl (ii); and T is a bond, Z.sup.i or a group (iii). The borneol esters can influence tubulin polymerisation and tubulin depolymerisation.

Abstract: This invention describes new, substituted 7.alpha.-(.xi.-aminoalkyl)-estratrienes of general formula I ##STR1## in which side chain SK is a radical of partial formula ##STR2## as well as their physiologically compatible addition salts with organic and inorganic acids.The new compounds represent compounds with very strong antiestrogenic action.The compounds according to the invention are, on the one hand, pure antiestrogens, or, on the other hand, antiestrogens with estrogenic partial action. Based on this spectrum of action, the new compounds are highly suitable for the production of pharmaceutical agents for tumor therapy and hormone replacement treatment.

Abstract: Stable, electroless, aqueous acidic gold bath, containing the tetracyano-(III) anion, a complexing agent, or a mixture of several complexing agents, and an acid, or a mixture of acids, and the use of these baths for the deposition of gold on metals which are less noble than gold or on alloys of these metals.

Abstract: Novel soluble oxidation resistant thrombomodulin analogs are produced for various therapeutic and other uses, such as in thrombotic and vascular disease therapies. These analogs exhibit the characteristic therapeutic properties of native thrombomodulin, yet they are soluble and are not inactivated after they have been exposed to oxidants. Some of the analogs disclosed are multifunctional fusion proteins having both antithrombotic activity and some additional bioactivity.

Abstract: This invention relates to novel 2-substituted-1(4)-aryl piperazines and to a process for their preparation. The compounds of this invention have been found to have cardiovascular, primarily antiarrhythmic effects.

Abstract: The present invention relates to thermoplastic polyamide resins for use in relief printing which are prepared by condensation of distilled and/or hydrogenated dimeric fatty acids, a mixture of oleic acid and isostearic acid, a substantially equivalent amount of ethylenediamine, and optionally co-diamines.